The Motley Fool
17 Sept 2026, 08:15 UTC · 1h ago
Verdict
Headline takes no side. We score LLY +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Eli Lilly holds 60% of the U.S. weight loss drug market, compared to Novo Nordisk's 38% share.
Priced inanalysis of existing market shares
So whatDominance in this high-growth segment supports the company's current $1.1T market capitalization.
More positive than 91% of claims this week
Novo Nordisk's oral Wegovy has 183,000 prescriptions, while Eli Lilly's Foundayo has 47,500.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inciting Citi analysts and IQVIA data
So whatLilly currently trails Novo by roughly 135,500 prescriptions in the oral segment.
More positive than 65% of claims this week
Eli Lilly's Foundayo allows for administration at any time of day on an empty or full stomach, unlike Novo's oral offering.
Priced inproduct feature analysis
More positive than 54% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company is described as a global leader in a hot growth market with a narrowing gap in the new oral drug segment.
More negative than 70% of ticker scores this week
While currently leading in oral prescriptions, the company is losing market share in injectables and seeing the lead narrow in pills.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
15h ago
—
LLY hasn't traded since this ran. Last close $1138.21 (Sep 16); the reaction starts at the next open.
LLY chart →
